1013635-15-8

Basic information

• Product Name: 3-(4-methoxyphenyl)-7-(oxiran-2-ylmethoxy)-4H-chromen-4-one
• Synonyms: 3-(4-methoxyphenyl)-7-(oxiran-2-ylmethoxy)-4H-chromen-4-one
• CAS NO: 1013635-15-8
• Molecular Weight: 324.333
• Mol File: 1013635-15-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-(4-methoxyphenyl)-7-(oxiran-2-ylmethoxy)-4H-chromen-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-methoxyphenyl)-7-(oxiran-2-ylmethoxy)-4H-chromen-4-one(1013635-15-8)
• EPA Substance Registry System: 3-(4-methoxyphenyl)-7-(oxiran-2-ylmethoxy)-4H-chromen-4-one(1013635-15-8)

Safety Data

• Hazardous Substances Data: 1013635-15-8(Hazardous Substances Data)

Upstream product

• 485-72-3 7-Hydroxy-3-(4-methoxy-phenyl)-chromen-4-on 
• 106-89-8 epichlorohydrin 
• 487-49-0 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone 

Downstream Products

• 1013635-19-2 7-(2-hydroxy-3-phenylpropoxy)-3-(4-methoxyphenyl)chromen-4-one 

Relevant articles and documents

New Aloperine–Isoflavone Conjugates

The reaction of aloperine with isoflavone glycidyl ethers was investigated. A series of alkaloid–isoflavonoid conjugates were synthesized via regioselective opening of the oxirane ring by aloperine.

Synthetic analogs of daidzein, having more potent osteoblast stimulating effect

A series of didzein derivatives were synthesized and assessed for stimulation of osteoblast differentiation using primary cultures of rat calvarial osteoblasts. Data suggested that three synthetic analogs, 1c, 3a and 3c were several folds more potent than daidzein in stimulating differentiation and mineralization of osteoblasts. Further, these three compounds did not show any estrogen agonistic activity, however had mild estrogen antagonistic effect. Out of the three compounds, 3c was found to maximally increase the mineralization of bone marrow osteoprogenitor cells. Compound 3c also robustly increased the mRNA levels of osteogenic genes including bone morphogenetic protein-2 and osteocalcin in osteoblasts. Unlike daidzein, 3c did not inhibit osteoclastogenesis. Collectively, we demonstrate osteogenic activity of daidzein analogs at significantly lower concentrations than daidzein.

ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION

Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.